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1. Introduction 
Diabetes is a metabolic disorder of fat, carbohydrate, and protein metabolism, characterized 
by resistance to the action of insulin, insufficient insulin secretion, or both. The two major 
classifications of diabetes mellitus (DM) are type 1 (insulin deficient) and type 2 (combined 
insulin resistance and relative deficiency in insulin secretion). They differ in clinical 
presentation, onset, etiology, and progression of disease. Two to five percent of pregnancies 
are complicated by diabetes, of which 90% are classified as gestational diabetes mellitus 
(GD) (Satman et al, 2002). GD is defined as glucose intolerance of variable severity which is 
first recognized during pregnancy, including individuals with previously undiagnosed 
diabetes as well as those in whom high glucose levels are provoked by pregnancy. This term 
should not be used for gravid women with previously diagnosed diabetes. GD has much in 
common with type 2 diabetes with similar genetic susceptibility, corresponding prevalence 
within a given population or ethnic group and similar risk factors. Both conditions can be 
considered as a mixture of insulin resistance (IR) and impaired insulin secretion. Indeed, GD 
is a predictor of future type 2 diabetes with a cumulative incidence of about 50% at 5 years. 
GD is also a predictor of the metabolic (resistance) syndrome and should probably be 
considered a cardiovascular risk factor for later life. Since its first description in the early 
1950s, GD has been one of the most controversial syndromes in the field of diabetes. 
Pregnancy is a state of insulin resistance, characterized by raised circulating insulin 
concentrations as the maternal pancreas compensates for increased peripheral demands. If 
adequate compensation does not occur, GD develops. GD is a well-established risk factor for 
adverse infant health outcomes, including fetal macrosomia, birth trauma, neonatal 
hypoglycemia, and fetal death (Cetin et al., 1997). GD can predict that the children of 
women who have GD are at an increased risk for obesity, glucose intolerance, and diabetes 
during adulthood. There is still confusion about the type of diagnostic tests and diagnostic 
criteria for GD and a screening protocol (e.g. universal versus selective screening). 
Gestational diabetes complicates about 1-14% of all pregnancies, depending on the 
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population and diagnostic tests that are used and ranges from mild degrees of 
hyperglycemia to insulin-dependent diabetes (Kim et al., 2007). 
Gestational diabetes usually manifests in the latter half of pregnancy and is characterized by 
insulin levels that are insufficient to meet insulin demands.  
2. Risk factors for GD  
Risk factors for GD include obesity, family history of diabetes, age greater than 35 years of 
age, pre-diabetes detected before pregnancy, previous delivery of babies with birth weights 
greater than 4 kg, sedentary lifestyles and some ethnical groups. The frequency of GD 
significantly increases with increasing number of risk factors. However, even a combination 
of risk factors does not reliably predict the likelihood of developing GD, missing up to 50% 
of cases in population based studies (Fraser & Heller, 2007;  Jang et al., 2003) estimates that if 
age > 30 years, obesity (BMI > 27.3), family history of diabetes mellitus and glycosuria in the 
present pregnancy were included as risk factors, 56.5% of the total population had risk 
factors for GD. However, in the stated report, the prevalence of GD in Korea was 2.0%, 
Thailand - 2.0% and U.S. Caucasians - 2.3%. One large study of women with GD showed 
that an increased incidence of GD was associated with age over 35, thin or obese 
prepregnancy weight, previous stillbirth, previous spontaneous or induced abortion, 
previous low- or high-birth-weight infant and chronic hypertension (Johnstone, 1999; 
Hossein-Nezhad et al., 2007) found the age distribution and GD prevalence in 15–24 age 
group was 0.39% and 2.68% in the 35–45 age group. The authors reported 33.33% of women 
with GD who had a positive family history of diabetes, compared with 10.3% of women in 
the normal group (p < 0.0001). It is now well established that women with a family history 
of diabetes had three times higher odds for GD than women without a family history of 
diabetes. Perhaps other maternal health and lifestyle behaviors, such as levels of physical 
activity, or selective immigration, could play an important role (Scholl et al., 2002). 
Obesity in pregnancy is increasing worldwide and is associated with increased risk of 
adverse outcomes for both mother and child. Maternal obesity is also accompanied by 
alterations in glucose metabolism and by perturbations in inflammatory markers, 
adipokines and vascular dysfunction. The link between obesity and IR has been recognised 
for many years and much of this association has been attributed to disturbances in 
adipocyte function and metabolism (Huda et al. 2010). Obesity has considerable effects on 
glucose metabolism in pregnancy with a loss of the reduction in fasting glucose in early 
pregnancy and significant enhancement of peripheral and hepatic IR. All women increase 
maternal fat stores in early pregnancy irrespective of prepregnancy adiposity to meet the 
feto-placental and maternal demands of late gestation and lactation. Normal pregnancy is 
associated with marked changes in glucose metabolism and IR to facilitate provision of fuel 
substrate for the fetus. In early pregnancy insulin secretion increases, while insulin 
sensitivity is unchanged, or even slightly improved. However, as pregnancy progresses, 
insulin-mediated glucose utilization worsens by 40–60% and insulin secretion increases 
several fold in order to maintain euglycaemia in the mother. The mechanisms for this 
increased risk are multifactorial and include effects on insulin signalling similar to those 
seen in obese non-pregnant women. Women of normal weight gain around 3.8 kg of fat 
during pregnancy although there is substantial variation. In women of normal weight the 
majority of fat is accumulated centrally in the subcutaneous compartment of the trunk and 
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upper thigh. A large population-based Swedish study highlighted that an increase in BMI of 
3 kg/m2 between two consecutive pregnancies resulted in an increased risk of pre-
eclampsia, GD, gestational hypertension, caesarean delivery, stillbirth and large for 
gestation age births even if a woman has a healthy BMI during pregnancy. (Villamor & 
Cnattingius, 2006; Hossein-Nezhad et al, 2007) It reported 35% prevalence of obesity (BMI of 
more than 27) in women with GD, compared with 11.3% in normal women (p < 0.0001). Not 
only weight gained during pregnancy, but  variations in body habitus or constitution, like 
high waist-hip ratios, short stature and higher body fat percentages at given BMI levels 
could contribute as a risk factors (Davis, 2008; Mensing et al., 2002; Scholl et al., 2002)  Not 
surprisingly, obese women are 4 times more likely and severely obese women almost 9 
times more likely to develop GD than lean women. 
Pregnancy is also characterised by marked increases in plasma lipid concentrations as 
gestation advances. Plasma cholesterol and triglyceride concentrations rise by 25–50% and 
200–400% respectively. The hyperlipidaemia of pregnancy is exaggerated further in obesity 
with higher serum triglyceride and very low density lipoprotein (LDL) cholesterol 
concentrations than those observed in lean women. This is seen together with lower high 
density lipoprotein (HDL) cholesterol, although LDL cholesterol and total cholesterol 
concentrations appear similar. This pattern of dyslipidaemia is similar to that of the 
metabolic syndrome in the non-pregnant population. Some of these pathways may well 
contribute to vascular and metabolic complications in obese pregnancy.  
It is well established that people with high levels of visceral or intra-abdominal body fat are 
associated with increased risk for type 2 diabetes (Huxley et al., 2008) and impaired glucose 
tolerance even after adjustment for BMI. Recent evidence suggests that even modest fasting 
hyperglycaemia (between 4.2 and 5.6 mmol/L), currently thought to be within normal 
limits, is linearly associated with adverse pregnancy outcomes including increased birth 
weight, caesarean delivery and neonatal hypoglycaemia (Huda et al, 2010). Women with a 
history of GD are metabolically vulnerable with insufficient ß-cell reserve, and many are IR. 
Approximately 17-63% of women who are diagnosed with GD during pregnancy will 
develop it in future pregnancies, and are at a much greater risk of developing type 2 
diabetes within 5-16 years. The risk varies with the magnitude of insulin resistance, for 
example, if the patient needed insulin in pregnancy or was noted to be obese, or developed 
GD before 24 weeks gestation, the risk is greater. There is also some evidence that further 
pregnancies accelerate the rate of decline of beta cell function in women with GD. Several 
studies have reported links between GD and the subsequent risk of type 2 diabetes. Recent 
meta-analysis reports that GD corresponds to a 7.4 fold increased risk for developing type 2 
diabetes mellitus (Bellamy et al., 2009). In addition, numerous studies have reported an 
increased risk of GD in women who are overweight or obese compared with lean or normal-
weight women (Chatzi et al., 2009). GD identifies pregnancies at increased risk for adverse 
perinatal outcome. It also identifies mothers who are at increased risk of developing type 2 
DM in the future and offers the possibility of interventions and early detection. Severity of 
glucose intolerance during pregnancy, insulin requirement during pregnancy, earlier 
diagnosis during pregnancy, family history of diabetes, recurrence of GD, increasing parity, 
maternal age, prepregnancy obesity, weight gain during and after pregnancy, presence of 
islet cell antibodies, and delivery of a macrosomic infant were reportedly the key risk factors 
for type 2 DM in women with history of GD (Cho et al., 2006). One of the major 
determinants of the risk for the development of subsequent type 2 diabetes is ethnic origin. 
Ethnic group with high risk of developing diabetes are Hispanic, African, Native American, 
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South or East Asian, Pacific Islands or Indigenous Australian. Women with previous GD 
have a higher prevalence of polycystic ovary syndrome (PCOS), which is a condition 
associated with IR. Similarly in a study of women with PCOS, GD developed in 20% of these 
women compared with only 9% of controls with an odds ratio of 1.9. Women with PCOS 
often attend assisted fertility clinics and should be warned of the likelihood of developing 
GD if they become pregnant (Hyer & Shehata, 2005; Metzger et al., 2010).  
Maternal diabetes during pregnancy exposes the fetus to hyperglycemia resulting in 
increased fetal insulin levels, which are associated with increased birth weight, increased 
childhood and adult obesity, and increased risk of GD and type-2 diabetes during 
childbearing age (Kim et al., 2007). 
Perinatal and maternal morbidity can be reduced by maintaining normoglycaemia in GD. 
To achieve good glycaemic control, women diagnosed with GD should monitor their blood 
glucose levels, exercise, and undergo nutrition counselling. Besides, medical treatment 
options should be incorporated in care plans. However, despite intensive treatment aiming 
at near normoglycemia, a surprisingly high risk of macrosomia and birth trauma has been 
reported among the neonates of mothers with GD. It would seem that the prevention of 
macrosomia should be the primary goal of GD management. Several studies suggest an 
increased rate of preeclampsia among women with GD, and a combination of maternal 
diabetes and pre-eclampsia is associated with poor perinatal outcome (Fan et al., 2006). 
Untreated or poorly controlled gestational diabetes can hurt the baby. It can raise the risk of 
certain pregnancy complications, like high blood pressure in the mother and having a 
larger-than-normal baby (macrosomia), which may require a C-section. Studies have shown 
that in GD the frequency of having an overweight baby is almost double, the frequency of 
having preeclampsia is almost double, and the frequency of early delivery is 40 percent 
greater. It was proven that the proper identification and management of GD are associated 
with a decrease in mortality and morbidity in infants.  
3. Testing programs 
GD is associated with maternal (pre-eclampsia, hypertension, caesarean section) and foetal 
morbidity (macrosomia, birth trauma, hypoglycaemia, hyperbilirubinemia, hypocalcemia, 
respiratory distress syndrome). Moreover, GD uncovers a pre-existing metabolic 
abnormality that may precede the development of overt diabetes mellitus. Therefore, 
prompt diagnosis of GD is essential to reduce maternal and foetal morbidity and to allow 
subsequent attempt at preventing or delaying the onset of Type 2 diabetes.  
Whether or not to screen for gestational diabetes is an issue of significant controversy. The 
ADA favors screening a woman who has risk factors for developing GD (e.g., severe obesity, 
personal history of GD or previous delivery of large-for-gestational age infant, glycosuria, 
PCOS or a strong family history of diabetes) at her first prenatal visit (American Diabetes 
Association [ADA], 2011). If test is abnormal, these individuals should be considered to 
have "overt" (not gestational) diabetes (ADA, 2010). If this screen is normal, testing should 
be repeated between weeks 24 and 28 of gestation. Pregnant women without these risk 
factors should undergo screening for GD between weeks 24 and 28 of gestation unless they 
are considered low risk. To be low risk, a woman must fulfill all the following criteria:  
 age younger than 25 years,  
 normal prepregnancy weight,  
 no known diabetes in first-degree relatives,  
www.intechopen.com
Prevalence and Risk Factors for the Development of GD in Some Eastern European  
Countries – Tendencies and Pharmacoeconomical Assessment for the Choice of Treatment 
 
73 
 not a member of an ethnic group with a high prevalence of GD,  
 no history of abnormal glucose tolerance,  
 no history of abnormal obstetric outcome. 
Screening for GD utilizes the oral glucose challenge test. New ADA guidelines (ADA, 2011) 
and WHO guidelines stated to perform a 75 g oral glucose tolerance test (OGTT), with 
plasma glucose measurement fasting and at 1 and 2 h at 24-28 weeks. OGTT should be 
performed in the morning after an overnight fast of at least 10 hours and after at least 3 days 
of unrestricted diet and unlimited physical activity. The patient should remain seated and 
should not smoke during the test (Johnstone, 1999). Criteria for diagnosis of GD based on 
the OGTT are summarized in Table 1. Two or more values must be met or exceeded for a 
diagnosis of diabetes to be made.  
 
Fasting ≥ 92 mg/dL (5.1 mmol/L) 
1 hour ≥ 180 mg/dL (10.0 mmol/L) 
2 hours ≥ 153 mg/dL (8.5 mmol/L) 
Table 1. Diagnosis of GD with a 75 g Glucose Load 
Results of the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study (Metzger et 
al., 2008), a large-scale (~25,000 pregnant women) multinational epidemiologic study, 
demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously 
increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously 
considered normal for pregnancy. For most complications there was no threshold for risk. 
These results have led to careful reconsideration of the diagnostic criteria for GD. The 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
recommended that all women not known to have prior diabetes undergo a 75 g OGTT at 24–
28 weeks of gestation. This probably will significantly increase the prevalence of GD, 
however there is mounting evidence that treating even mild GD reduces morbidity for both 
mother and baby (International Diabetes Federation [IDF], 2004). Women at high risk should 
be screened as soon as feasible. If the initial screening is negative they should undergo 
retesting at 24 to 28 weeks’ gestation. 
There are two principles (selective and universal) in testing which need to be distinguished. 
First, there is selective (or at-risk) clinical need for high risk patient (obesity, a family history 
of diabetes, a history of macrosomic stillbirth, etc.). Second, there is universal screening, for 
women not clinically identified as being at particular risk. Universal screening is more 
sensitive, while selective screening is less costly. Unfortunately, the use of risk factors for 
individuals is not very effective, can result in great inconsistencies, and is a source of 
uncertainty for obstetricians and midwives. Universal screening should, at the moment, 
depend on the local prevalence of type 2 DM in the reproductive age group. Low-risk status 
requires no glucose testing, but this category is limited to those women meeting all of the 
following characteristics: age <25 years, normal weight before pregnancy, member of a 
population with a low prevalence of GD, no known diabetes in first-degree relatives, no 
history of abnormal glucose tolerance, no history of poor obstetric outcome. Where type 2 
DM is common (for example many units in the USA, Saudi Arabia and the Gulf, and certain 
ethnic minorities), then a total population screen is justified (Forsbach et al., 1997). Universal 
screening is more sensitive and more practical when a family history of diabetes cannot be 
obtained reliably (Karcaaltincaba et al., 2009). The diagnosis of GD is associated with a risk 
of type 2 diabetes later in life, so it is unsurprising that the prevalence of GD in any 
www.intechopen.com
 
Gestational Diabetes 
 
74
population will be largely determined by those factors which predict such a risk (Fraser & 
Heller, 2007) 
Any woman diagnosed with GD should be screened for diabetes 6–12 weeks postpartum 
and should be followed up with subsequent screening for the development of diabetes or 
pre-diabetes. If the fasting plasma glucose (FPG) level is normal, then reassessment for DM 
should occur every 3 years. Family planning for subsequent pregnancies should be 
discussed, and monitoring for the development of symptoms of DM should be undertaken. 
The goal of treatment is to reduce the risks of GD for mother and child by keeping blood 
glucose levels equal to those of pregnant women who don't have such a disease. The highest 
risk of complications is established when there is an increase of the initial level of pre-
prandial blood sugar and when there is an increase of the postprandial glucose.   
Scientific evidences show that controlling glucose levels can result in less serious fetal 
complications and increased maternal quality of life and insulin administered twice daily 
during the third trimester to mothers who have even a mild degree of hyperglycemia will 
reduce fetal size, and in particular fetal adiposity. The proper management GD includes 
special meal plans and scheduled physical activity and of course - daily blood glucose 
testing. The further steps may require insulin injections. 
4. Prevalence of GD  
GD is the most common metabolic disease of pregnancy.  The prevalence of GD varies 
across the globe, as well as between racial and ethnic groups within the same country. In 
recent years there has been a reported increased trend in the prevalence of GD throughout 
the world, with huge health-care and economic costs (Bellamy et al., 2009). This is 
particularly the case in developed countries, such as the USA, the UK, Australia, China and 
New Zealand (Sinha et al., 2003; Ferrara et al., 2004; Joshy & Simmons, 2006; Metzger & 
Counstan, 1998; Fan et al., 2006; Carolan et al., 2010). The increased prevalence has been 
recently disputed, suggesting that more cases were identified through more aggressive 
universal screening. For example, Lopez-de-Andres et al. (Lopez-de-Andres et al., 2011) did 
not found increase in the prevalence of GD is Spain from 2001 to 2008. This partly coud be 
explained with the fact that with the selective approach, women at low risk for GD do not 
need to be screened and some cases could be missed. Several teams have tried to improve 
the sensitivity of selective screening by making the relevant protocols more inclusive. 
Through this ‘tinkering’, age has emerged as the most important risk factor for type 2 DM 
and, by extension, gestational diabetes. Accordingly, the lower threshold for screening has 
decreased from 30 years in earlier studies to 25 years in more recent ones.  
Approximately 8% of all pregnancies with wide-ranging differences between countries 
(ranging from 1 to 16% depending on the population studied, screening protocols and 
diagnostic criteria used) are complicated by GD (Hossein-Nezhad et al., 2007). Furthermore, 
within the same country, the prevalence of GD is strongly influenced by race and culture. 
High prevalence rates have been reported in studies from Australia (Indian-born 15%, 
Chinese 13.9%) and the United States (Zuni Indians 14.3%).  
Increasing prevalence relates to a range of factors including advanced maternal age, obesity 
and migratory patterns (Ferrara et al., 2004; Joshy & Simmons, 2006). Of particular interest 
here is the increase seen among specific ethnic groups (Joshy & Simmons, 2006, Kim et al., 
2007), which may relate to ethnic differences in maternal glucose concentrations (Scholl et 
al., 2002; Esakoff et al., 2005) and recent trends of obesity (Harris et al., 1997, Xiong et al., 
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2001, Rosenberg et al., 2003; Ben-Haroush et al., 2004). Moreover, women of non-Caucasian 
ethnicity represent a considerable portion of childbearing populations in developed 
countries, and as rates of obesity and GD grow, there is a concordant increase in the risk of 
poorer pregnancy outcomes among these groups. GD is also associated with an increased 
maternal likelihood of developing diabetes type 2 in later life, and recent research postulates 
a link between GD, childhood obesity and later onset of diabetes in the offspring (Ferrara, 
2007; Ricart et al., 2005; Carolan et al., 2010) 
USA 
In the USA more than 200,000 cases annually are complicated by GD (Bottalico, 2007). Only 
1.5–2% of Midwestern white women develop GD, while up to 15% of Native American 
women from southwestern USA have been reported to develop GD. In the Hispanic, 
African-American and Asian populations of the USA, the incidence of GD is 5–8%. Most 
women will return to normoglycemia postpartum, but 30% to 50% will develop type 2 DM 
or glucose intolerance later in life. State-, city-, hospital-level GD prevalence estimates have 
consistently shown GD rates to be higher among Asian and Pacific Islander (API) mothers 
than among white, black, or Hispanic mothers (Lawrence et al., 2008; Chu et al., 2009) found 
that among 3,108,877 births, US APIs had a substantially higher age-adjusted prevalence of 
GD (6.3%) than whites (3.8%), blacks (3.5%), or Hispanics (3.6%). 
Asia 
Oriental populations have different demographic characteristics (maternal age, height, BMI 
and frequency of obesity) to other ethnic populations and it is not clear to what extent the 
effects of age and obesity are interrelated. In Korea the life styles have changed rapidly to a 
westernized pattern characterized by sedentary occupations and consumption of refined 
food and a high-fat diet. Therefore it is reasonable to predict that the prevalence of GD in 
Korean women will increase as the prevalence of type 2 DM increases in the developing 
countries (Jang et al., 1995; 2003). The overall prevalence of GD in Korean women was 
estimated as 2.2%. The patients with GD were older, shorter and had a higher prepregnancy 
weight, BMI and parity than normal controls. The prevalence of GD in women with a single 
risk factor was 1.3% higher than that in women without risk factors (0.6%, p < 0.05), but was 
lower than that in the population at large (2.2%). However the prevalence increased to 
33.3% in patients with 4 risk factors. 
The DECODA study showed that India has a higher prevalence of diabetes than China or 
Japan (Ferrara, 2007) reported 3.8% prevalence of GD in China (20512 women screened), 
however they could not determine if there is an increase in the incidence of GD, but state 
that it is possible that absolute rate of GD has increased in China, probably due to changes 
in the lifestyle, decreased physical activity and increased incidence of obesity.  Shai et al. 
(Shai et al., 2006) found that Asian women had a higher risk of diabetes than White, 
Hispanic, or Black women. In addition, they found that weight gain increased risk of 
diabetes more for Asian than for other women. Hunsberger et al. (Hunsberger et al., 2010) 
found that, compared with women of other race/ethnicities, both high BMI and low BMI 
Asian women were at the greatest risk of having GD. Additionally, diabetes risk among 
Asians seems to increase with prolonged exposure to Western lifestyle. The Turkish 
Diabetes Epidemiology Study reported the highest prevalence of diabetes in southern 
Turkey compared with northern and central parts of Turkey (Satman et al., 2002). The 
approximately rate of GD in Turkey is 4% (Karcaaltincaba et al., 2009). 
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Europe 
Di Cianni et al. (Di Cianni et al., 2003) performed a retrospective study to evaluate the 
prevalence of GD by using both the selective and the universal screening approach and the 
presence of risk factors for GD in a cohort of Italian women. From June 1st, 1995 to December 
31st, 2001, universal screening for GD was performed in 3950 women. In this analysis GD was 
significantly and independently associated to age, pre-pregnancy BMI, weight gain, height 
and family history of diabetes. The generated figures indicate that GCT was positive in 35.2% 
of cases, while the true prevalence of GD was 8.7%. When the OGTT was performed in a 
random sample of women with negative GCT, about 6.5% were found to have GD. By 
extrapolation to the whole cohort, it was then calculated that the approximate true prevalence 
of GD in the general population can be as high as 12.3%.Lopez-de-Andres et al. (Lopez-de-
Andres et al., 2011) reported the prevalence of GD is Spain from 2001 to 2008 to be 3.6%. In 
Sweden, 7817 infants (of total number 892084) were born of mothers with GD between 1992 
and 2004.  This represents an incidence of GD of 0.9% in the studied population (Ahlsson et al., 
2010). The number of adults with diabetes in the European region is expected to reach 55.2 
million. And 33.40% are from the eastern European region. 
Eastern Europe 
The prevalence of GD in Eastern Europe and especially in Bulgaria shows a very diverse 
prevalence. (IDF, 2011)  
 
Country percent  with 
diabetes 
 (20-79 years) 
2010 
number of 
people with 
diabetes  
2010 
percent  with 
diabetes 
 (20-79 years) 
2030 
population GDP nominal 
total (USD) 
1. Albania 4.8 102 800 5.1 2 986 952 12.224 billion 
2. Belarus 9.1 661 100 9.0 9 648 533 52.887 billion 
3. Bosnia and 
Herzegovina 
9.1 271 100 8.6 3 842 566 16 631 billion 
4. Bulgaria 9.0 519 500 7.8 7 351 234 44.843 billion 
5. Croatia 9.2 315 900 8.0 4 486 881 59 917 billion 
6. Estonia 9.9 97 900 9.0 1 340 021 19.123 billion 
7. Greece 8.8 754 000 7.4 11 305 118 325 088 billion 
8. Latvia 9.9 169 700 9.0 2 217 969 23 955 billion 
9. Lithuania 9.7 239 800 9.0 3 244 000 35.152 billion 
10. Macedonia 8.0 119 300 8.0 2 052 722 9470 billion 
11. Moldova 8.7 233 500 9.0 3 567 500 5 403 billlion 
12. Montenegro 8.4 35 700 8.0 620 000  
13. Romania 8.4  1 351 400 8.0 21 959 278 158 393 billion 
14. Russia 9.0 9 624 900 9.0 142 905 200 1 477 trillion 
15. Serbia  8.6 613 400 8.0 9 981 929 43.6 billion 
16. Ukraine 9.6 3 328 400 9.0  49 100 000 37.6 billion 
Table 2. The DM morbidity in Eastern European region. 
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According to the data, provided by the Diabetes Atlas, Estonia, Latvia and Ukraine are 
those eastern European countries with highest percentage of diabetes for 2010. Albania is 
the country with lowest percentage. Totally 18 438 400 is the number of the patients with 
diabetes in these sixteen countries. The mean percentage with diabetes for 2010 is 8.76. 
And the decrease for the next 20 years will be insignificant – 8.24. Of course all the eastern 
European countries are extremely diverse as the population and gross domestic product 
(GDP) are taken in mind. Russia is the richest, while Moldova, Macedonia and Albania 
are the poorest. The number of deaths attributable to diabetes (20-79 years) is 317 955. 
And there is no significant differentiation by sex 143 810 – males and 174 145 – females. A 
very interesting fact is that only five countries - Greece, Russia, Belarus, Ukraine and 
Romania have National Diabetes program according to a survey of International Diabetes 
Federation (IDF) member associations. Bulgaria for example is working in order to 
develop and implement a national diabetes program. The Bulgarian Diabetes Association 
(BDA) that is the only one national representative association for patients and diabetics in 
Bulgaria is working towards achieving this goal. It was created in 1990. On the initiative 
of the Group for parliamentary consensus to combat socially significant diseases in the 
40th National Assembly of Bulgaria and under the auspices of the National Assembly on 
2-3 February 2008 in Plovdiv, Bulgaria there was a consensus around three significant 
acts:  
1. Restriction of diabetes in Bulgaria and particularly the preparation and implementation 
of diabetic register and national program to combat diabetes should be one of the 
priorities of all institutions in Bulgaria.  
2. It is the creation of a working group of representatives of all stakeholders to draw up an 
action plan for prevention, early diagnosis and proper treatment of diabetes in Bulgaria. 
These documents must be submitted for consideration and adoption by the National 
Assembly during the autumn session of 2008.  
3. After the program and action plan, responsible institutions is imperative to take all 
necessary actions to ensure adequate funding for their practical application in the 
country. So we can conclude that Bulgaria is working towards the development of a 
National program. 
Of course not only the disease itself has to be assessed but also the complication that 
accelerates the mortality. Close to four million deaths in the 20-79 age group may be 
attributable to diabetes in 2010, accounting for 6.8% of global all-cause mortality in this age 
group. According to the literay sources - this number resembles the deaths in this age group 
from several infectious diseases. The highest number of deaths due to diabetes is expected to 
occur in countries with large populations as they have the largest numbers of people with 
diabetes like Russia.  
Another very important aspect is the health expenditures per person with diabetes in 2010. 
As it can be seen there are very big fluctuations in the Eastern European region. For example 
Greece spent 2742 USD, while Moldova – only 76 USD. In order to be precise in the 
conclusions it has to be analyzed the GDP in order to compare these expenditures. For 
Greece it is 325 088 billion USD , while for Moldova – 5 403 billlion. For Greece these mean 
health expenditures per person with diabetes are 0.0084% from the GDP of the country, 
while for Moldova – 0.014%. Bulgaria spent 0.007% from the GDP of the country for 
treatment of a patient with diabetes. (IDF, 2011) 
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Country Mean health expenditure per person with diabetes  
in 2010 (USD) 
Albania 261 
Belarus 238 
Bosnia and Herzegovina 307 
Bulgaria 301 
Croatia 736 
Estonia 584 
Greece 2 742 
Latvia 493 
Lithuania 521 
Macedonia 287 
Moldova 76 
Montenegro 14 
Romania 145 
Russia 261 
Serbia  238 
Ukraine 307 
Table 3. Mean health expenditures per person with DM in 2010 for the Eastern European 
region. 
The statistics by country for gestational diabetes shows that apporximatelly 1 in 2 014 or 
0.05% or 135 000 women get GD every year in the USA. The analysis of the data for the 
eastern European region are shown in Table 4.  
 
Country Extrapolated 
Incidence 
Population estimated used 
(US Census Bureau, International data 
base 2004) 
Albania 1 759 3 544 808 
Belarus 5 117 10 310 520 
Bosnia and 
Herzegovina 
202 407 608 
Bulgaria 3 731 7 517 973 
Croatia 2 231 4 496 869 
Estonia 665 1 341 664 
Greece 5 284 10 647 529 
Latvia 1 144 2 306 306 
Lithuania 1 790 3 607 899 
Macedonia 1 012 2 040 085 
Romania 11 095 22 355 551 
Russia 71 457 143 974 059 
Serbia  and 
Montenegro 
5 373 10 825 900 
Ukraine 23 690 47 732 079 
Table 4. Extrapolated incidence of GD (wrongdiagnosis.com, 2011) 
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These statistics are calculated extrapolations of various prevalence or incidence rates against 
the populations of a particular country or region. The statistics used for 
prevalence/incidence of GD are typically based on US, UK, Canadian or Australian 
prevalence or incidence statistics, which are then extrapolated using only the population of 
a given country. The base is that 0.05% from the population (women) will get GD annually. 
The literary data shows that the frequency of development of GD varies from 2 to 4-5 % 
from the pregnant women. Some authors even state that 9% from the pregnant women 
develop GD. In Bulgaria a pilot study shows that the frequency is even greater – 14%, but till 
today there was not perform a systematic screening. Unfortunatelly in Bulgaria there is a 
tendency for doubling the GD morbidity, because of the obesity and because of the increase 
survival rate of girls born with weight above 4 kg. 
5. St. Vincent declaration – Review and principles 
In 1989, in St. Vincent, Italy was signed the St. Vincent declaration, a joint initiative of the 
International Diabetes Federation European region and the WHO European regional office. 
It is a program for strategic action to reduce the human and economic burden of diabetes in 
Europe and has been adopted by most of the European governments. (IDF, 2004) The St. 
Vincent initiative has few target areas, which seek to improve the quality of life of people 
with diabetes and to promote education of patients so to prevent diabetes complications. 
Patient education is very important and a team approach, including physicians, pharmacists 
and nurses, is beneficial. Some of the main conclusions during the meeting were that 
“diabetes mellitus is a major and growing European health problem, a problem at all ages 
and in all countries. It currently threatens at least ten million European citizens. It is within 
the power of national governments and health departments to create conditions in which a 
major reduction in this heavy burden of disease and death can be achieved. Countries 
should give formal recognition to the diabetes problem and deploy resources for its 
solution. Plans for the prevention, identification and treatment of diabetes and particularly 
its complications should be formulated at local, national and European regional levels. 
General goals and five-year targets can be achieved by the organised activities of the 
medical services in active partnership with diabetic patients, their families, friends and 
workmates and organisations in: 
 The management of their own diabetes and education for it. 
 The planning, provision and quality audit of health care. 
 National, regional and international organisations for disseminating information about 
health maintenance. 
 Promoting and applying research. (IDF, 2004) 
The St. Vincent’s declaration outlined the following general goals for children and adults 
with diabetes: 
 sustained improvement in health experience and a life experience approaching normal 
expectation in quality and quantity. 
 prevention and cure of diabetes and its complications by intensifying research effort. 
The five-year targets that are granted in the declaration are: 
 elaboration, initiation and evaluation comprehensive programmes for the detection and 
control of diabetes and its complications with self-care and community support as 
major components. 
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 steps for raising the awareness in the population and amongst health care professionals 
of the present opportunities and the future needs for the prevention of diabetes and its 
complications. 
 organisation training and teaching programs in diabetes management and care for 
people of all ages with diabetes, for their families, friends and working associates and 
for the health care team. 
 ensuring that care for children with diabetes is provided by individuals and teams 
specialised in the management of both diabetes and children, and that families with a 
diabetic child get the necessary social, economic and emotional support. 
 reinforcement of the existing centres of excellence in diabetes care, education and 
research.  
 promotion of independence, equity and self-sufficiency for all people with diabetes, i.e. 
children, adolescents, those in the working years of life and the elderly. 
 attempts for reducing the hindrances to the fullest possible integration of the diabetic 
citizen into society. 
 implementation of  effective measures for the prevention of costly complications: 
 
a reduce new blindness due to diabetes by one third or more. 
b reduce the number of people entering end-stage diabetic renal failure by at least 
one third. 
c reduce by one half the rate of limb amputations for diabetic gangrene. 
d cut morbidity and mortality from coronary heart disease in the diabetic by 
vigorous programmes of risk factor reduction. 
e achieve a pregnancy outcome in the diabetic woman that approximates that of 
the non-diabetic woman. 
 
 establishment of monitoring and control systems, using new information technology for 
quality assurance of diabetes health care revision and for laboratory and technical 
procedures in diabetes diagnosis, treatment and self-management. 
 promotion and granting of collaboration of European and international programmes of 
diabetes research and development through national, regional and World Health 
Organisation agencies and in active partnership with diabetes patients’ organisations. 
 taking urgent action in the spirit of the WHO programme ‘Health for All’ to establish 
joint initiative between the WHO and the International Diabetes Federation (European 
region) to initiate, accelerate and facilitate the implementation of these 
recommendations.” (IDF, 2004) 
Since 1989 further implementation and evaluation meetings have been held in Budapest 
(1992), Athens (1995), Lisbon (1997) and Istanbul (1999), where representatives of ISPAD 
have helped to formulate recommendations on behalf of children and adolescents. 
6. Pharmacoeconomical assessment of GD drug treatment. The role of the 
pharmacist for GD management 
The standard treatment of GD is insulin treatment. The metabolic control target in the GD 
treatment is blood sugar before meal under 5.8 mmo/l, postprandial blood sugar under 7.5 
mmo/l and hemoglobin HbA1-c under 6.5%. The postprandial blood glucose is of critical 
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importance for the neonatal end of the pregnancy. That is why it is very important to 
determine the cost and effectiveness of the drug treatment for women with GD. It can be 
achieved by studying the clinical effectiveness of the treatment with diet and diet + insulin 
for pregnant women with GD and determination of the ratio treatment cost/effectiveness. A 
prospective study of 50 women with gestational diabetes from Sofia, Bulgaria were studied 
from pharmacoeconomical point of view. They were divided into 2 groups: Group I (n = 30) - 
pregnant women only on a diet and Group II (n = 20) - pregnant women treated by a diet and 
insulin. The following including criteria were applied: age above 18 years, one fetus 
pregnancy, insignificant additional disease without organ damages, without infectious 
diseases, without obesity and HbA1-c under 7%. The key excluding criteria are the availability 
of diabetes before pregnancy, or prior insulin therapy, treatment with oral hypoglycemic 
drugs before pregnancy, income of drugs that have influence on the carbohydrate tolerance, 
existing obstetrics complications till the demonstration of the gestation diabetes. The diet 
treatment was with diet No 9 according to M.I. Pevzner. The diet satisfies the 
recommendations for feeding. Human insulin, in intensified insulin regimen type- bazal-
prandial, including treatment with three doses rapid acting insulin and one or two doses 
intermediate acting insulin was applied. The total costs of the treatment of a patient, on a diet 
without complications in the peripartal period is 335.02 USD and is lower in comparison with 
the total cost of the treatment of a woman treated only with insulin that is 347.42 USD. 
(p=0.04). The difference in the treatment cost is 12.40 USD. The total treatment cost of a 
pregnant woman, treated with diet with complications in the peripartal period is 363.94 USD 
and is also lower in comparison with the total cost of the treatment of a woman treated with 
insulin and with complications that is 398.90 USD (p=0,03). (Todorova et al., 2007) 
The cost-effectiveness coefficient is calculated based on the total direct medical costs, used 
for the reduction of the average 24-houred glucose under 5,8 mmol/l as for higher precision 
the calculations are proceeded with the received difference in the level of the glycated 
hemoglobin after the treatment. (Todorova et al., 2007) The over calculated CCE for 100 
women is CCE is 5141.17 USD  
CCE= 398.90 – 363.94/6,1 – 5,42 = 51.4117USD 
51.4117x 100 = 5141.17 USD 
The so calculated coefficient reflects the costs for complications that is saved by the insulin 
treatment and that should occur after an ineffective diet treatment. The interpretation of this 
coefficient shows that the spent 12.40 USD for insulin treatment for every woman in fact 
saves 51.41 USD that should be spent for the treatment of unfavorable peripartal maternal 
complications. Through the application of a model of mathematical modeling the total final 
cost for one beneficially treated woman with GD is calculated. The calculations for the two 
therapeutical alternatives are performed by the use of the probabilities for occurrence of 
effective treatment for each of them. 
The total costs of the treatment with diet is 351.69 USD  
(334.43 x 0,4) + (363.2x 0,6) = 351.69 USD 
The total cost of the treatment with insulin is 349.35 USD.  
(346.84x0,95) + (398.2x0,05) = 349.35 USD 
The applied analytical model shows that on the base of the higher per cent successfully 
treated women, the spent final costs for successfully treated woman after the treatment with 
insulin are 388,13 USD (349.32/0,9), and the final costs after the treatment with diet are 879.1 
USD  (351.64/0,4). (Todorova et al., 2007) 
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Table 5. “Three of decisions” of the alternatives for the treatment of GD. 
There are four clinical paths, concerning diabetes that are included in the list of the 
Bulgarian Health Insurance fund. Unfortunatelly there is no clinical path concerning DM or 
the complications of this disease that decreases the accessibility towards proper 
management of this disease. And on this base it can be explained the prospective data about 
doubling the GD morbidity. 
 
Clinical 
path No 
disease 
Hospital 
stay 
Drug treatment 
Prize 
(USD)/daily 
8 Diabetes polineuropathia  3 days 
 carbamazepine - 400-
800 mg/daily. 
 gabapentin – from 3 
times x 300 mg till 1500 
mg daily; 
 pregabalin – up to 2 х 
150 mg; 
0.23-0.46 
2.34 – 3.90 
 
3.92 
104 
Decompensated DM for 
patients above 18 years 
3 days 
 Insulin 
 Electrolities  9.57 - once 
105 
Decompensated DM for 
patients bellow 18 years 
3 days 
 Insulin 
 Electrolities  9.57 - once 
178 
Surgical Intervention Of 
Diabetic Foot without 
vessel reconstruction 
3 days   
Table 6. Clinical paths in Bulgaria, concerning diabetes. 
Another aspect that is innovative in the Bulgarian pharmaceutical practice, concerning the 
management of GD is the role of the pharmacist as a health-care educator in order to be 
accomplished the St. Vincent declaration aims is demonstrated. Patient education is very 
important and a team approach, including physicians, pharmacists and nurses, is 
beneficial.(38). A study that included pregnant women attending antenatal clinic with GD 
January 2009 - December 2009 demonstrated the beneficial role of patients education. The 
following including criteria are used: age above 18 years, one-fetus pregnancy, GD, 
insignificant additional disease without organ damage, without infectious diseases. The 
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study design is a pilot case-control study that includes 45 women with GD from city of 
Sofia, Bulgaria. The pregnant women were divided into two groups – Group I (n=22), that 
were educated on the proper management of their disease and were on a diet and treated 
with insulin, and Group II (n=23), that were not educated and on a diet, but treated with 
insulin on a regimen, prescribed by the physician. The assignment was based on the 
principle of random numbers through custom random number generator. The educational 
program continued 3 months. It was designed and adapted to the patients comfort, 
provided at the pharmacy they are attending. The course was presented to the 22 previously 
selected pregnant women with GD.  
The educational course included the following teaching units: 
- The essence of GD; 
- The complication of improper disease management; 
- Proper diet regimen (based on the Sample GD diet menu of the Endocrinology clinic of 
Minneapolis) and also proper drug treatment as well as hypo-and hyperglycaemia and 
physical activity for both of the groups. 
The first unit acquainted each of the women with the aim of the educational program, 
provided general concept about GD and about self-monitoring and emphasized on the 
active patient participation in the treatment. The personal information of each of the patients 
was collected, concerning the duration of the disease, the prescribed drug treatment if any, 
the frequency of the hypoglycaemic and hyperglycaemic incidents. At the end of the first 
unit, each of the patients was supplied with written materials on the essence of GD. The goal 
was to learn the seriousness of GD. 
The main topic discussed during the second teaching unit was complication of improper 
management. The educator explained the complications of GD. The educator discussed with 
every woman the effects on the fetus. 
The main topic discussed during the third teaching unit was proper diet regimen (based on 
the GD diet menu of the Endocrinology clinic of Minneapolis, USA). At the end of the session 
the patients were supplied with the Sample GD diet menu. Each of the patients was supplied 
with written materials on proper nourishing for diabetic patients and physical activity.  
The educational materials used during the program included:  
- a set of one-page written materials that illustrate the most important aspects of every 
educational lecture, provided to the patient after every session;  
- questionnaire cards for distribution among the participants as a standardized 
procedure for assessment of their knowledge acquired in the previous educational 
units;  
- individual food and activity record for the self-monitored data (food, total grams of 
carbs, comments and activities, insulin treatment);  
In the beginning and at the end of the educational process a patient satisfaction 
questionnaire was applied (Diabetes Questionnaire (IMG)). During the 3-months education 
and its end, the observed behavioural parameters performed changes. The results from the 
twice-applied questionnaire assessing the quality of life of the patients in the beginning and 
in the end of the educational programme show that the five main indices have been 
improved with on the average of 5% for the both groups, but greater for those included in 
Group I (Table 7). The greater increase was observed in the positive changes in the mood – 
7,9% for Group I and 8,2% for Group II , followed by number of days “being easy” with 6.9 
% for Group I and with 6,2% for Group II (6.7%) and possibility to perform physical 
activities 5.8 % for Group I and 5% for Group II. It could be considered that the educational 
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process affects both the physical and the psychological well-being and thus it is beneficial 
for the global patient’s quality of life.  
 
 Time period 
Variable 0 3 month 
 Group I Group II Group I Group II 
QL-positive changes in the mood  10,8% 9,9% 18,7% 18,1% 
QL-increase in days “being easy” 18,4% 17,9% 25,3% 24,1% 
QL- increase in social activity 11,1% 12,2% 14% 15,1% 
QL- increase in days being “rested” 15% 14,5% 17,4% 16,8% 
QL- increase in physical activity 13,4% 14,0% 19,2% 19,0% 
total 68,70% 68,50% 94,60% 93,10% 
mean 13,74% 13,70% 18,92% 18,62% 
Data are %. QL – “quality of life”. 
Table 7. Changes in the patients sample after the educational process 
The advanced pharmacy practitioner in diabetes management is a relatively new approach. 
The role of the pharmacist in it, integrates drug management, patients’ compliance 
assessment, blood glucose monitoring, skills training, prospective and retrospective drug 
utilization review, adverse drug reaction and toxicity screening and education of the 
patients.(Valentine et al, 2003). These skills in fact are not new for the pharmacist but their 
introduction, as systematized approach in everyday practice should correspond to the local 
circumstances. To match the context of the pharmaceutical care, defined by the APA as 
“Patient-centered, outcomes-oriented pharmacy practice that requires the pharmacist to 
work in concert with the patient to promote health, to prevent disease and to assess, 
monitor, initiate and modify medication use”, is a real challenge for the management of 
diabetes, especially for Bulgaria.(American Pharmaceutical Association [APA], 2011). 
Despite the relatively small sample size, this study shows the role of education program for 
improvement of patient’s outcomes. The results confirm the necessity of individual 
approach in the selection of therapeutic strategy for the women with GD. As the St. Vincent 
declaration assumed, the quality of life of people with diabetes has to be improved and to be 
promoted education of patients so to prevent diabetes complications. According to the St. 
Vincent declaration the aim of the treatment of GD is the achievement of child birth similar 
to the child birth by women without diabetes.(IDF, 2004) In this project are involved all 
healthcare givers, including the pharmacists in order to be achieved the goals. (Douglas et 
al., 2000; Dixon, 2002; Campbell et al., 1990; Mensing et al., 2002) The educational approach 
is a necessary step for better management of the disease in order to minimize the risk of 
maternal and fetal complications and the pharmacists are capable to perform it. The results 
obtained confirm the need for consistent patients’ education, using variety of educational 
models, as an essential part of the diabetes care that will result in improvement of patient’s 
quality of life.  
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7. Conclusion 
Gestational diabetes is a subject of endless debate, uncertainty and confusion. Although it is 
a alteration during pregnancy, the true prevalence of GD remains a matter of discussion. 
The prevalence of GD in the general population is varied from 1% to 16% depending on 
both the country of origin and the nature of the indigenous population. The rate can vary 
due to differences in data collection methods, low response rates, non-random selection of 
the women, and lack of uniformity in the diagnostic criteria. More recently, the high rate of 
GD has been claimed to be an unrealistic estimation caused by universal screening, not 
carrying any specific benefit for pregnancy outcome.  
GD is considered to be a state of prediabetes. The diagnosis of GD identifies women at high 
risk of diabetes after the pregnancy. Therefore, it is important for these women who may 
develop type 2 diabetes during their life to take preventive measures as well as to prevent 
pregnancy-related complications. It is well known that raised glucose levels in women with 
GD increase both morbidity and mortality among their offspring due mainly to an increased 
incidence of congenital abnormalities and excessive fetal growth in the third trimester. 
Women with a family history of diabetes had three times higher odds for GD than women 
without a family history of diabetes. With the prevalence of type 2 diabetes increasing 
across the world, and given that the prevalence of GD is thought to shadow that of type 2 
diabetes, most populations will expect to see a rise in GD figures during the coming years. It 
is very important to establish clear policies to ensure that those at risk are reliably identified, 
appropriately treated during pregnancy and then equipped to make the necessary lifestyle 
changes to try and prevent them developing type 2 diabetes in later life.  
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